Richard A Lafayette
Overview
Explore the profile of Richard A Lafayette including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
1457
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heerspink H, Jardine M, Kohan D, Lafayette R, Levin A, Liew A, et al.
Kidney Int Rep
. 2025 Jan;
10(1):217-226.
PMID: 39810771
Introduction: Endothelin A (ETA) receptor activation is a driver of proteinuria, kidney inflammation, and fibrosis in IgA nephropathy (IgAN). Atrasentan, a selective ETA receptor antagonist, has potential to reduce proteinuria...
2.
Salmon E, Carlozzi N, Lai J, Spino C, Wang Y, Capellari E, et al.
Glomerular Dis
. 2024 Oct;
4(1):172-182.
PMID: 39473996
Introduction: Fluid overload is a source of substantial morbidity for adults and children with nephrotic syndrome (NS). Preparation and Rationale for a Fluid Overload in Nephrotic Syndrome Clinical Outcomes Assessment...
3.
Heerspink H, Jardine M, Kohan D, Lafayette R, Levin A, Liew A, et al.
N Engl J Med
. 2024 Oct;
392(6):544-554.
PMID: 39460694
Background: Patients with IgA nephropathy and severe proteinuria have a high lifetime risk of kidney failure. The efficacy and safety of the selective endothelin type A receptor antagonist atrasentan in...
4.
Bomback A, Herlitz L, Kedia P, Petersen J, Yue H, Lafayette R
J Am Soc Nephrol
. 2024 Oct;
36(3):487-499.
PMID: 39392695
Background: Complement 3 (C3) glomerulopathy is a rare autoimmune disorder characterized by activation of the alternative complement pathway with isolated or dominant complement 3 deposition in glomeruli. Patients with C3...
5.
Barratt J, Lafayette R, Floege J
Front Med (Lausanne)
. 2024 Aug;
11:1461879.
PMID: 39211339
Immunoglobulin A nephropathy (IgAN) often has a poor outcome, with many patients reaching kidney failure within their lifetime. Therefore, the primary goal for the treatment of IgAN should be to...
6.
7.
Palmer M, Royal V, Jennette J, Smith A, Liu Q, Ambruzs J, et al.
Glomerular Dis
. 2023 Nov;
3(1):248-257.
PMID: 38021464
Introduction: Cure Glomerulonephropathy (CureGN) is an observational cohort study of patients with minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), or IgA nephropathy. We developed a conventional,...
8.
Cheung C, Barratt J, Carroll K, Lafayette R, Liew A, Suzuki Y, et al.
Clin J Am Soc Nephrol
. 2023 Oct;
19(3):394-398.
PMID: 37801688
No abstract available.
9.
Lafayette R, Charu V
Adv Ther
. 2023 Sep;
40(12):5557-5566.
PMID: 37751024
Complement 3 glomerulopathy (C3G) is an ultra-rare, progressive kidney disease resulting from dysregulation of the alternative complement pathway. Clinical presentation of C3G is heterogeneous and definitive diagnosis relies on kidney...
10.
Caster D, Lafayette R
Am J Kidney Dis
. 2023 Sep;
83(2):229-240.
PMID: 37742867
IgA nephropathy (IgAN) is the most common glomerular disease in the world. However, the approach to treatment remains controversial. There has been an explosion of clinical trials over the past...